Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles

被引:24
作者
Machado, Rogerio Bonassi [1 ]
de Melo, Nilson Roberto [2 ]
Maia, Hugo, Jr. [3 ]
Cruz, Achilles Machado [1 ]
机构
[1] Fac Med Jundiai, Dept Obstet & Ginecol, Jundiai Sch Med, BR-13202550 Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Med, Dept Obstet & Gynecol, BR-05403990 Sao Paulo, Brazil
[3] CEPARH, BR-44015340 Salvador, BA, Brazil
关键词
Oral contraceptive; Ethinylestradiol; Drospirenone; Continuous use; Metabolic profile; Blood coagulation; ORAL-CONTRACEPTIVES; ETHINYL ESTRADIOL; MU-G; WOMEN; METABOLISM; ACCEPTABILITY; ASSOCIATION; PARAMETERS;
D O I
10.1016/j.contraception.2009.08.009
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Background: The objective of this study was to evaluate the effects of a contraceptive pill containing ethinylestradiol (30 mcg) and drospirenone (3 mg) in a continuous regimen on lipid, carbohydrate and coagulation parameters. Study Design: This open, prospective, randomized study included 78 participants (mean age 27.8 years) who were randomized into two groups to use the pill continuously for 168 days or for six 28-day cycles with a 7-day hormone-free interval between cycles. Markers of lipid, carbohydrate and coagulation profiles were measured prior to initiation and after the 6 months of pill use. Results: No statistically significant differences were found between the two contraceptive regimens with respect to carbohydrate or lipid profiles or in the parameters related to coagulation. Conclusions: The contraceptive combination of ethinylestradiol and drospirenone used in a continuous regimen was associated with metabolic alterations similar to those found during the traditional cyclic regimen of oral contraceptive use. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:102 / 106
页数:5
相关论文
共 17 条
[1]
Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms [J].
Apter, D ;
Borsos, A ;
Baumgärtner, W ;
Melis, GB ;
Vexiau-Robert, D ;
Colligs-Hakert, A ;
Palmer, M ;
Kelly, S .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2003, 8 (01) :37-51
[2]
Chandra Anjani, 2005, Vital Health Stat 23, P1
[3]
A prospective study of oral contraceptives and NIDDM among US women [J].
ChasanTaber, L ;
Willett, WC ;
Stampfer, MJ ;
Hunter, DJ ;
Colditz, GA ;
Spiegelman, D ;
Manson, JE .
DIABETES CARE, 1997, 20 (03) :330-335
[4]
An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables [J].
Endrikat, J ;
Klipping, C ;
Cronin, M ;
Gerlinger, C ;
Ruebig, A ;
Schmidt, W ;
Düsterberg, B .
CONTRACEPTION, 2002, 65 (03) :215-221
[5]
Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth [J].
Fu, HS ;
Darroch, JE ;
Haas, T ;
Ranjit, N .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (02) :56-63
[6]
Amenorrhea associated with contraception - an international study on acceptability [J].
Glasier, AF ;
Smith, KB ;
van der Spuy, ZM ;
Ho, PC ;
Cheng, L ;
Dada, K ;
Wellings, K ;
Baird, DT .
CONTRACEPTION, 2003, 67 (01) :1-8
[7]
Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women - The CARDIA study [J].
Kim, C ;
Siscovick, DS ;
Sidney, S ;
Lewis, CE ;
Kiefe, CI ;
Koepsell, TD .
DIABETES CARE, 2002, 25 (06) :1027-1032
[8]
Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism [J].
Klipping, C ;
Marr, J .
CONTRACEPTION, 2005, 71 (06) :409-416
[9]
Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial [J].
Kwiecien, M ;
Edelman, A ;
Nichols, MD ;
Jensen, JT .
CONTRACEPTION, 2003, 67 (01) :9-13
[10]
Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg) [J].
Machado, RB ;
Fabrini, P ;
Cruz, AM ;
Maia, E ;
Bastos, AD .
CONTRACEPTION, 2004, 70 (05) :365-370